Background: Sarcoidosis is a systemic granulomatous disease with unknown etiology and an unpredictable clinical course. Serum chitotriosidase (CTO) is one of the most reliable biomarkers of sarcoidosis and its activity has been related with active disease. Aim: AND OBJECTIVES: We evaluated the clinical utility of CTO and other biomarkers in a large cohort of patients with sarcoidosis, in order to investigate the potential correlation between biomarkers and specific clinical phenotypes of disease. Methods: CTO activity, Angiotensin Converting Enzyme (ACE) and Lysozyme levels were calculated in a population of 778 sarcoidosis patients, regularly followed at the Sarcoidosis Regional Referral Centre in Siena, and in 104 healthy controls. Clinical characteristics and functional assessment of steroid-naïve patients with high chitotriosidase activity (HCA) were retrospectively collected in detail to identify clinical features associated with the biomarker's over-expression. Results: Significantly higher CTO activity, ACE and Lysozyme levels were observed in sarcoidosis patients than in healthy controls (p<0.0001, p<0.0001 and p<0.01, respectively). Patients with pulmonary symptoms and extrapulmonary localizations of disease reported the highest CTO activity. After steroid therapy, CTO and Lysozyme, but not ACE, were significantly reduced. Conclusion: CTO is a non-invasive, reproducible and useful biomarker in the clinical practice; high CTO activity may predict extrapulmonary involvement of disease and could be useful to identify patients requiring pharmacological treatments.
Cameli, P., Bargagli, E., Bennett, D., Bianchi, N., Refini, R.M., Rottoli, P., et al. (2017). Human chitotriosidase analysis: a reliable biomarker of sarcoidosis severity. In Published By European Respiratory Society Print ISSN 0903-1936 Online ISSN 1399-3003 History Published online December 6, 2017.. 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND : EUROPEAN RESPIRATORY SOC JOURNALS LTD [10.1183/1393003.congress-2017.PA3272].
Human chitotriosidase analysis: a reliable biomarker of sarcoidosis severity
Cameli, P.;Bargagli, E.;Bennett, D.;Bianchi, N.;Refini, R. M.;Rottoli, P.;Cillis, G.
2017-01-01
Abstract
Background: Sarcoidosis is a systemic granulomatous disease with unknown etiology and an unpredictable clinical course. Serum chitotriosidase (CTO) is one of the most reliable biomarkers of sarcoidosis and its activity has been related with active disease. Aim: AND OBJECTIVES: We evaluated the clinical utility of CTO and other biomarkers in a large cohort of patients with sarcoidosis, in order to investigate the potential correlation between biomarkers and specific clinical phenotypes of disease. Methods: CTO activity, Angiotensin Converting Enzyme (ACE) and Lysozyme levels were calculated in a population of 778 sarcoidosis patients, regularly followed at the Sarcoidosis Regional Referral Centre in Siena, and in 104 healthy controls. Clinical characteristics and functional assessment of steroid-naïve patients with high chitotriosidase activity (HCA) were retrospectively collected in detail to identify clinical features associated with the biomarker's over-expression. Results: Significantly higher CTO activity, ACE and Lysozyme levels were observed in sarcoidosis patients than in healthy controls (p<0.0001, p<0.0001 and p<0.01, respectively). Patients with pulmonary symptoms and extrapulmonary localizations of disease reported the highest CTO activity. After steroid therapy, CTO and Lysozyme, but not ACE, were significantly reduced. Conclusion: CTO is a non-invasive, reproducible and useful biomarker in the clinical practice; high CTO activity may predict extrapulmonary involvement of disease and could be useful to identify patients requiring pharmacological treatments.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1255782